Allied Corp. Advances Psilocybin Product Psilonex™ RX and Initiates Manufacturing Process

Allied Corp. (ALID) is pleased to announce that it has initiated the manufacturing activities for Psilonex™ RX – Allied’s proprietary psilocybin product, Allied announced its manufacturing agreement with HAVN Life Sciences to manufacture Psilonex™ RX under their legal licenses and manufacturing process.

Recommended AI News: Mastercard Acquires CipherTrace To Enhance Crypto Capabilities

Over the past months, Allied’s scientists have further developed the Psilonex™ RX formulation and, through Allied’s licensed manufacturing partner, has initiated the manufacturing process for the production of the medicine. This psilocybin product includes a proprietary formulation of extracted psilocybin, other functional mushroom extracts as well as a proprietary vitamin constituency.

Allied has what it believes to be a unique approach to treatment of general depression, anxiety and PTSD. Initially, patients are to be prescribed Psilonex™ RX (the psilocybin-based product) followed by a daily product of cannabidiol (CBD) called Psilonex™ Daily.

Under the direction of Mr. Jim Smeeding, Director and VP of Pharma of Allied Corp, Psilonex™ RX has been formulated as a specific concentration ratio of functional mushrooms, vitamins and psilocybin. Allied intends to bring Psilonex™ RX through to the completion of human clinical phase I trials, and then intends to seek a licensing arrangement with a big pharma partner.

“The anecdotal evidence we have obtained has guided our formulation of Psilonex™ RX. We believe we are working with real people with real world mental health concerns. In our view, Psilonex™ RX is showing great promise to help individuals who have given of their lives to help their country,” said Mr. Jim Smeeding, Director and VP of Pharma of Allied Corp.

Recommended AI News: Lookout Recognized in Eleven Gartner® Hype Cycle™ Reports